Department of Neurology, School of Medicine, University of California, Davis, Sacramento, California.
Phytother Res. 2020 Jun;34(6):1268-1281. doi: 10.1002/ptr.6617. Epub 2020 Feb 15.
Natural polyphenols are being tested both in preclinical and clinical settings for the treatment of different neurological disorders. The article describes the outcome of three polyphenols, resveratrol, epigallocatechin gallate, and quercetin, in preclinical animal models of epilepsy (both acute and chronic) and epileptogenesis. In theory, the antioxidant and neuroprotective properties of these natural polyphenols might be valuable in the management of acute seizures and the prevention of epileptogenesis. It is fascinating to observe that these polyphenols have a capacity to alter various signaling processes involved in the pathogenesis of epilepsy. The antiepileptic or antiseizure potential with these molecules delivers a mixed outcome. Some studies have demonstrated the usefulness of these molecules in preclinical models of epilepsy; however, contrary to the findings also exist. These molecules have poor bioavailability that may remain as the limiting factor in their clinical effects. The use of nanotechnology and other techniques have been tested to enhance bioavailability and brain penetration. There are no randomized double-blinded clinical studies establishing their antiepileptic effects in humans. It is concluded that more preclinical mechanism-based studies are needed to deliver a more certain picture regarding the use of natural polyphenols in the treatment of epilepsy.
天然多酚类化合物正在临床前和临床环境中进行测试，以治疗不同的神经紊乱。本文描述了三种多酚类化合物（白藜芦醇、表没食子儿茶素没食子酸酯和槲皮素）在癫痫（急性和慢性）和癫痫发生的临床前动物模型中的结果。从理论上讲，这些天然多酚类化合物的抗氧化和神经保护特性在急性发作的治疗和癫痫发生的预防中可能具有价值。有趣的是，这些多酚类化合物具有改变与癫痫发病机制相关的各种信号转导过程的能力。这些分子的抗癫痫或抗惊厥潜力产生了混合结果。一些研究表明，这些分子在癫痫的临床前模型中有用；然而，也存在相反的发现。这些分子的生物利用度差，这可能仍然是其临床效果的限制因素。已经测试了纳米技术和其他技术的使用，以提高生物利用度和脑穿透。目前还没有随机双盲临床试验确定它们在人类中的抗癫痫作用。因此，需要更多基于临床前机制的研究，以更确定地了解天然多酚类化合物在治疗癫痫中的应用。
